These data suggest that the relatively consistent relationship noted between the β1-AR Gly389Arg variant and the response to β-AR-blocker therapy and heart failure previously reported on13-15 is unlikely to be determined by an association between genotype and the risk for the expression of the clinical phenotype of heart failure, the severity of heart failure or the progression of the disease. Here, ADRB2 is linked to heart failure.